{"entity":{"id":"julien-hadoux","kind":"person","name":"Julien Hadoux","aka":[],"tldr":"Paris endocrine oncologist who was lead author of LIBRETTO-531, the trial that showed the selective RET inhibitor selpercatinib beats older kinase inhibitors as first treatment for advanced medullary thyroid cancer.","summary":"Julien Hadoux is an endocrine oncologist at Gustave Roussy who treats thyroid and neuroendocrine cancers. He was first author of the 2023 New England Journal of Medicine report of LIBRETTO-531, the phase 3 trial in which selpercatinib lengthened progression-free survival compared with cabozantinib or vandetanib in untreated RET-mutant advanced medullary thyroid cancer, establishing the selective RET inhibitor as first-line therapy.","asOf":"2026-09-18","links":[],"tags":["thyroid","targeted-therapy","trialist"],"related":[],"cancers":["medullary-thyroid-cancer","thyroid"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-libretto-531-nejm-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Endocrine oncologist, Gustave Roussy","institutionId":"gustave-roussy","specialisms":["Medullary thyroid cancer","RET inhibitors","Neuroendocrine tumours"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hadoux%5BAuthor%5D"}],"papers":[],"orcid":"0000-0002-1276-3289"},"route":"/people/julien-hadoux/","neighbours":{"cancer":[{"id":"medullary-thyroid-cancer","kind":"cancer","name":"Medullary thyroid cancer","route":"/cancers/medullary-thyroid-cancer/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"institution":[{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/"}],"paper":[{"id":"paper-libretto-531-nejm-2023","kind":"paper","name":"LIBRETTO-531: selpercatinib versus cabozantinib or vandetanib in advanced RET-mutant medullary thyroid cancer","route":"/key-papers/paper-libretto-531-nejm-2023/"}]}}